A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 2-phase study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and gemcitabine.

The study has 2 parts. In the first part of the study, Phase 1, patients with advanced/metastatic solid tumors will receive increasing doses of study drug in combination with gemcitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 24 patients from the US will be enrolled in Part 1 (Completed).

In the second part of the study, Phase 2, patients with metastatic pancreatic cancer will receive the best dose of study drug, in combination with gemcitabine, determined from the first part of the study and will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 42 patients from the US will be enrolled in Part 2 (Withdrawn).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

NCT00761345

Pancreatic Carcinoma Non-resectable Metastatic Pancreatic Cancer

COMPLETED PHASE1

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

NCT01010945

Advanced Pancreatic Cancer

COMPLETED PHASE1

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

NCT03600623

Locally Advanced Pancreatic Cancer Borderline Pancreatic Inoperable Cancer Pancreatic Cancer

TERMINATED EARLY_PHASE1

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

NCT01729481

Metastatic Pancreatic Adenocarcinoma

UNKNOWN PHASE2

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

NCT00769483

Pancreatic Cancer Pancreatic Adenocarcinoma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARRY-334543 + gemcitabine

Group Type EXPERIMENTAL

ARRY-334543, EGFR/ErbB2 inhibitor; oral

Intervention Type DRUG

multiple dose, escalating

Gemcitabine, nucleoside analogue; intravenous

Intervention Type DRUG

multiple dose, single schedule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ARRY-334543, EGFR/ErbB2 inhibitor; oral

multiple dose, escalating

Intervention Type DRUG

Gemcitabine, nucleoside analogue; intravenous

multiple dose, single schedule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of a solid tumor suitable for treatment with gemcitabine.
* No more than 3 prior anticancer regimens for advanced disease.
* Measurable or evaluable, nonmeasurable disease.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
* Able to take and retain oral medications.
* Additional criteria exist.

Exclusion Criteria

* Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days).
* Treatment with prior chemotherapy within 21 days of first dose of study drug.
* Requiring IV alimentation.
* Pregnancy or lactation.
* Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
* History of being unable to tolerate gemcitabine or any of its components.
* Additional criteria exist.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No